Breast cancer is the most frequent neoplasm in women. 1 Its pathophysiology is complex and include activation of the human epidermal growth factor receptor 2, activation of hormone receptors such as the estrogen receptor (ER) and/or progesterone receptor (PR), and BRCA mutations. 2 Patients with breast neoplasms that express ER and/or PR are candidates for antiestrogen agent (AEA) therapy, 3 including ER inhibitor (tamoxifen) and aromatase inhibitors (letrozole, anastrozole, and exemestane). 4 One of the main adverse events reported with AEA therapy is musculoskeletal symptoms, especially arthralgia, which is reported in up to 50% of patients. 5 Despite the high prevalence of this symptom, the subjacent arthropathy is not well defined. We believe that AEA therapy-associated arthralgias in some patients may be a form of estrogen-dependent polyarticular osteoarthritis (OA), a similar condition that occurs in postmenopausal patients in a hypoestrogenic state. 6 In the present study, we show a series of patients with symptomatic arthropathy that developed after the start of AEA therapy.Based on clinical and imaging data, an approximation is made to characterize this type of arthropathy.
| MATERIAL S AND ME THODS
| Study designA single-center, observational study was conducted in Cali, Colombia. Patients with joint pain and AEA therapy referred to the Unit of Rheumatology at Fundación Valle del Lili between 2011 and 2022 were included.